Page last updated: 2024-12-06
fendosal
Description
Fendosal, also known as N-methyl-N-(2,6-dimethylphenyl)-2-(1H-indol-3-yl)acetamide, is a synthetic compound that has shown promising pharmacological activities. Its synthesis involves a multi-step process starting with indole and 2,6-dimethylaniline. Fendosal exhibits various effects, including anti-inflammatory, analgesic, and antipyretic properties. These effects are attributed to its ability to inhibit the enzyme cyclooxygenase (COX), which plays a role in the production of prostaglandins, inflammatory mediators. Its potential therapeutic applications in pain management and inflammation have led to extensive research efforts to understand its mechanisms of action and optimize its pharmacological profile. Researchers are particularly interested in its selectivity for COX-2, an isoform of COX that is primarily involved in inflammation, as this selectivity could potentially minimize the gastrointestinal side effects associated with non-selective COX inhibitors.'
fendosal: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
fendosal : A benzoindole that is 4,5-dihydro-3H-benzo[e]indole in which the nitrogen is substituted by a 3-carboxy-4-hydroxyphenyl group. A non-narcotic analgesic and non-steroidal anti-inflammatory drug, it has greater analgesic and inflammatory responses than aspirin but with less gastrointestinal toxicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 40821 |
CHEMBL ID | 2106146 |
CHEBI ID | 135595 |
SCHEMBL ID | 24967 |
MeSH ID | M0066428 |
Synonyms (56)
Synonym |
2-hydroxy-5-{2-phenyl-3h,4h,5h-benzo[e]indol-3-yl}benzoic acid |
n-(3-carboxy-4-hydroxy)phenylpyrrole |
benzoic acid, 5-(4, {5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-2-hydroxy-} |
2-hydroxy-5-(2-phenyl-4,5-dihydro-3h-benzo[e]indol-3-yl)benzoic acid |
2-hydroxy-5-(2-phenyl-4,5-dihydrobenzo[e]indol-3-yl)benzoic acid |
{5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)salicylic} acid |
hp-129 |
p 71-0129 |
nsc-351522 |
alnovin |
fendosal |
53597-27-6 |
5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)salicylic acid |
nsc351522 |
benzoic acid,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-2-hydroxy- |
hp 129 |
3-(3-carboxy-4-hydroxyphenyl)-2-phenyl-4,5-dihydro-3h-benz(e)indole |
c25h19no3 |
brn 1665211 |
nsc 351522 |
benzoic acid, 5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)-2-hydroxy- |
fendosalum [inn-latin] |
5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)salicylic acid |
5-(4,5-dihydro-2-phenyl-3h-benz(e)indol-3-yl)-2-hydroxybenzoic acid |
fendosal (usan/inn) |
D04145 |
alnovin (tn) |
5-(4,5-dihydro-2-phenyl-3h-benzo[e]indol-3-yl)salicylic acid |
CHEBI:135595 |
fendosalum |
FT-0650710 |
A7798 |
BCP9000007 |
AKOS015919538 |
CHEMBL2106146 |
p-71-0129 |
5-20-08-00484 (beilstein handbook reference) |
unii-9z709558tz |
fendosal [usan:inn:ban] |
9z709558tz , |
BCP0726000191 |
fendosal [usan] |
fendosal [mi] |
fendosal [inn] |
SCHEMBL24967 |
3-(3-carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole |
HAWWPSYXSLJRBO-UHFFFAOYSA-N |
DTXSID80201811 |
BCP03561 |
AS-35147 |
fendozal |
mfcd00866078 |
hp 129; nsc 351522; p 71-0129 |
Q27273407 |
5-(4,5-dihydro-2-phenyl-3h-benz[e]indol-3-yl)-salicylic acid |
2-hydroxy-5-(2-phenyl-4,5-dihydro-benzo[e]indol-3-yl)-benzoic acid |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
"Fendosal has a much wider separation of effective and gastric-irritating doses than does aspirin." | ( Fendosal (HP 129): a potent anti-inflammatory and analgesic compound. Agnew, MN; Allen, RC; Anderson, VB; Lassman, HB; Novick, WJ; Wilker, JC, 1978) | 2.42 |
"Fendosal has a much wider separation of effective and gastric-irritating doses than does aspirin." | ( Fendosal (HP 129): a potent anti-inflammatory and analgesic compound. Agnew, MN; Allen, RC; Anderson, VB; Lassman, HB; Novick, WJ; Wilker, JC, 1978) | 2.42 |
Bioavailability
Roles (2)
Role | Description |
non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
non-narcotic analgesic | A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
pyrroles | An azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton. |
benzoindole | |
monohydroxybenzoic acid | Any hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
AID1144896 | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior to 1%, sc carrageenan challenge measured after 3 hrs | 1976 | Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
| Carboxyarylindoles as nonsteroidal antiinflammatory agents. |
AID1144899 | Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 120 mins prior to 1%, sc carrageenan challenge measured after 3 hrs | 1976 | Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
| Carboxyarylindoles as nonsteroidal antiinflammatory agents. |
AID1131966 | Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior challenge measured after 3 hrs relative to placebo-control | 1977 | Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
| Synthesis of carboxyarylindoles and benzofurans as nonsteroidal antiinflammatory agents. |
AID1144897 | Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior to 1%, sc carrageenan challenge measured after 3 hrs | 1976 | Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
| Carboxyarylindoles as nonsteroidal antiinflammatory agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 19.13 (24.57) | Research Supply Index | 2.64 (2.92) | Research Growth Index | 4.14 (4.65) | Search Engine Demand Index | 15.26 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 3 (30.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (70.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |